Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Director · President and COO | February 02, 2026 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date February 02, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 96,100 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 96,100 · Balance 96,100 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2036-02-01 | Direct | 336,300 |
Reported balance
After 2026-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-02 · Grant · Acquired 336,300 · Balance 336,300 F3: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F3: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2026 Filed Feb 5, 2026 16:44 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 18,675 | $0.00 | $0.00 |
DisclosureSEC source: 0002045027-26-000002 · form4-02052026_090256.xml · derivative · entry 2 Davis Hugh M. · CIK 0002045027 · Director · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,025 Underlying: Common Stock · 18,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 16:44 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 18,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002045027-26-000002 · form4-02052026_090256.xml · nonDerivative · entry 1 Davis Hugh M. · CIK 0002045027 · Director · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 02, 2026 Filed Feb 6, 2026 18:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 336,300 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0002045027-26-000004 · form4-02062026_110205.xml · derivative · entry 2 Davis Hugh M. · CIK 0002045027 · Director · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,300 Underlying: Common Stock · 336,300 shares Expires 2036-02-01 F3 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 02, 2026 Filed Feb 6, 2026 18:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 96,100 | $0.00 | $0.00 |
DisclosureSEC source: 0002045027-26-000004 · form4-02062026_110205.xml · derivative · entry 1 Davis Hugh M. · CIK 0002045027 · Director · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,100 Underlying: Common Stock · 96,100 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 16:50 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 26,750 | $0.00 | $0.00 |
DisclosureSEC source: 0002045027-25-000003 · form4-12042025_091242.xml · derivative · entry 2 Davis Hugh M. · CIK 0002045027 · Director · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,250 Underlying: Common Stock · 26,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to the Continuous Service (as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to the Continuous Service (as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 16:50 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 26,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002045027-25-000003 · form4-12042025_091242.xml · nonDerivative · entry 1 Davis Hugh M. · CIK 0002045027 · Director · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 261,600 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001415889-25-002942 · form4-02042025_040211.xml · derivative · entry 2 Davis Hugh M. · CIK 0002045027 · Director · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,600 Underlying: Common Stock · 261,600 shares Expires 2035-02-02 F3 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 74,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002942 · form4-02042025_040211.xml · derivative · entry 1 Davis Hugh M. · CIK 0002045027 · Director · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,700 Underlying: Common Stock · 74,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 17:42 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 107,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028178 · form4-12032024_101234.xml · derivative · entry 2 Davis Hugh M. · CIK 0002045027 · Director · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,000 Underlying: Common Stock · 107,000 shares Expires 2034-12-01 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F1 · shares: The securities were granted pursuant to the Issuer's 2024 Inducement Plan (the "Plan") as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). F4 · derivative.exercise_date: Four year vesting with 25% of the shares subject to the restricted stock units vesting on each of the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to recipient's Continuous Service through each such date. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 17:42 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 375,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001415889-24-028178 · form4-12032024_101234.xml · derivative · entry 1 Davis Hugh M. · CIK 0002045027 · Director · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2034-12-01 F1 · shares: The securities were granted pursuant to the Issuer's 2024 Inducement Plan (the "Plan") as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). F2 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of December 2, 2024 (in each case rounded down to the nearest whole share, except for the last vesting installment), subject to recipient's Continuous Service (as defined in the Plan) through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.